IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes

scientific article published on 16 December 2011

IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/HEP.24678
P698PubMed publication ID22180014
P5875ResearchGate publication ID230478605

P50authorDarius MoradpourQ28322833
Zoltán KutalikQ30435012
Laurent AbelQ30503755
Markus H HeimQ39188870
Etienne PatinQ41561223
Stephanie BibertQ42761880
Thierry PoynardQ43252014
Bertrand NalpasQ50737298
Pierre-Yves BochudQ50877821
Jean-François DufourQ61977955
Stanislas PolQ87747574
Gladys MartinettiQ98684608
P2093author name stringHans Hirsch
Marc Bourlière
Francesco Negro
Beat Müllhaupt
Ioannis Theodorou
Andreas Cerny
Julien Guergnon
Stephan Regenass
Nicolas Goossens
Swiss Hepatitis C Cohort Study Group
Lorenz Kuske
Raffaele Malinverni
ANRS HC EP 26 Genoscan Study Group
Guenter Dollenmaier
Meri Gorgiewski
Tillman Gerlach
P2860cites workIFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complexQ24336912
Genetic variation in IL28B and spontaneous clearance of hepatitis C virusQ24596340
IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaquesQ24630281
Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunityQ24642027
Lambda interferon inhibits hepatitis B and C virus replicationQ27469456
Simultaneous evaluation of lymphocyte subpopulations in the liver and in peripheral blood mononuclear cells of HCV-infected patients: relationship with histological lesionsQ27480734
Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanomaQ28235086
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceQ28255243
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association studyQ28269827
Antitumor activity of IFN-lambda in murine tumor modelsQ28585272
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groupsQ29614459
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyQ29614896
Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseQ29614930
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the LiverQ29616866
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis CQ29619541
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.Q31040495
Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic responseQ34116121
EASL Clinical Practice Guidelines: management of hepatitis C virus infectionQ34168383
Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivoQ34647423
Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammationQ36291657
Antitumor activity of type I and type III interferons in BNL hepatoma modelQ36425910
Review article: predicting response in hepatitis C virus therapyQ36447562
What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C?Q37389916
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).Q40166878
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kineticsQ40211546
In-situ immunophenotyping study of hepatic-infiltrating cytotoxic cells in chronic active hepatitis C.Q42983312
Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C.Q42988942
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infectionQ42989510
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.Q42990025
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infectionQ42997865
Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.Q42997975
Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosisQ43033159
Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS).Q43039935
The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infectionQ43042435
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapyQ43049563
Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agentsQ43251298
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfaQ43279592
Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C.Q43836377
Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C.Q44598567
Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infectionQ44703198
Intrahepatic and peripheral blood virus-specific cytotoxic T lymphocyte activity is associated with a response to combination IFN-alpha and ribavirin treatment among patients with chronic hepatitis C virus infectionQ45510333
Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infectionQ57160250
IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCCQ58493937
P433issue2
P407language of work or nameEnglishQ1860
P921main subjecthepatitis CQ154869
Hepatitis C virusQ708693
P304page(s)384-394
P577publication date2011-12-16
P1433published inHepatologyQ15724398
P1476titleIL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes
P478volume55